colorectal cancer
Conditions
Interventions
Screening group for high-risk groups of colorectal cancer:None
Colorectal cancer postoperative group(Stages ?-?):None
Sponsors
The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Screening group inclusion criteria (a) Age range from 50 to 74 years old, regardless of gender; Agree to provide timely feedback on tumor related results in the health examination report to the researchers; (b) At least one of the following situations must be met: i. First degree relatives with a history of colorectal cancer; ii. Have a history of intestinal polyps or adenomas; iii. Inflammatory bowel disease (including ulcerative colitis and Crohn's disease) that has not healed for more than 8 years; iv. Fecal occult blood test positive. (c) Having full capacity for civil conduct; (d) Agree to promptly provide feedback to the researchers on information related to tumor diagnosis during external hospital visits during the research process; (e) Willing and able to sign an informed consent form. Postoperative inclusion criteria (a) Histopathologically confirmed colorectal cancer with imaging stage I-III; (b) At least 18 years of age, regardless of gender; (c) To undergo radical resection; (d) ECOG score =1; (e) Enrolled patients were newly diagnosed and did not receive surgery, radiotherapy, chemotherapy, targeted therapy, or other tumor-related interventions; (f) Complete medical records; (g) Those who understand and voluntarily sign the informed consent, subjects whose compliance is determined by the investigator.
Exclusion criteria
Exclusion criteria: Screening group exclusion criteria (a) Previous history of malignant tumor; (b) Is receiving any cancer-related treatment; (c) Those who have received major surgical treatments such as blood transfusions or transplants within three months; (d) Participate in other interventional clinical investigators within 3 months; (e) Those with autoimmune diseases, genetic diseases, mental disorders/disabilities, etc. that the investigator deems unsuitable for participation in the study; (f) Poor compliance, judged by the researcher to be unable to complete the study. Exclusion criteria for postoperative group (a) MSI-H or dMMR; (b) Non-primary bowel cancer; (c) Had a blood transfusion during or within 2 weeks prior to surgery; (d) With other intestinal malignancies; (e) Pregnant or lactating women; (f) Preoperative neoadjuvant radiotherapy/chemotherapy; (g) Failure to follow up the trial plan on time; (h) The sample quality does not meet the test requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| circulating tumor DNA (ctDNA) methylation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Carcinoembryonic antigen (CEA); | — |
Countries
China
Contacts
Public ContactXiaomin Dong
The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital)
Outcome results
None listed